Literature DB >> 20683980

Noonan syndrome associated with both a new Jnk-activating familial SOS1 and a de novo RAF1 mutations.

Mauro Longoni1, Silvia Moncini, Mariangela Cisternino, Ilaria M Morella, Serena Ferraiuolo, Silvia Russo, Savina Mannarino, Valeria Brazzelli, Paola Coi, Renata Zippel, Marco Venturin, Paola Riva.   

Abstract

Noonan syndrome is a genetic condition characterized by congenital heart defects, short stature, and characteristic facial features. Familial or de novo mutations in PTPN11, RAF1, SOS1, KRAS, and NRAS are responsible for 60-75% of the cases, thus, additional genes are expected to be involved in the pathogenesis. In addition, the genotype-phenotype correlation has been hindered by the highly variable expressivity of the disease. For all these reasons, expanding the genotyped and clinically evaluated case numbers will benefit the clinical community. A mutation analysis has been performed on RAF1, SOS1, and GRB2, in 24 patients previously found to be negative for PTPN11 and KRAS mutations. We identified four mutations in SOS1 and one in RAF1, while no GRB2 variants have been found. Interestingly, the RAF1 mutation was present in a patient also carrying a newly identified p.R497Q familial SOS1 mutation, segregating with a typical Noonan Syndrome SOS1 cutaneous phenotype. Functional analysis demonstrated that the R497Q SOS1 mutation leads to Jnk activation, but has no effect on the Ras effector Erk1. We propose that this variant might contribute to the onset of the peculiar ectodermal traits displayed by the propositus amidst the more classical Noonan syndrome presentation. To our knowledge, this is the first reported case of a patient harboring mutations in two genes, with an involvement of both Ras and Rac1 pathways, indicating that SOS1 may have a role of modifier gene that might contribute the variable expressivity of the disease, evidencing a genotype-phenotype correlation in the family. Copyright 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683980     DOI: 10.1002/ajmg.a.33564

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  9 in total

1.  SOS1 Gain-of-Function Variants in Dilated Cardiomyopathy.

Authors:  Jason R Cowan; Lorien Salyer; Nathan T Wright; Daniel D Kinnamon; Pedro Amaya; Elizabeth Jordan; Michael J Bamshad; Deborah A Nickerson; Ray E Hershberger
Journal:  Circ Genom Precis Med       Date:  2020-06-30

2.  Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment.

Authors:  Anna Papadopoulou; Michalis Issakidis; Evangelia Gole; Konstantina Kosma; Helen Fryssira; Andreas Fretzayas; Polyxeni Nicolaidou; Sophia Kitsiou-Tzeli
Journal:  Eur J Pediatr       Date:  2011-05-18       Impact factor: 3.183

3.  Differential allelic expression of SOS1 and hyperexpression of the activating SOS1 c.755C variant in a Noonan syndrome family.

Authors:  Silvia Moncini; Maria Teresa Bonati; Ilaria Morella; Luca Ferrari; Riccardo Brambilla; Paola Riva
Journal:  Eur J Hum Genet       Date:  2015-02-25       Impact factor: 4.246

4.  A rasopathy phenotype with severe congenital hypertrophic obstructive cardiomyopathy associated with a PTPN11 mutation and a novel variant in SOS1.

Authors:  Jill A Fahrner; Aisha Frazier; Suha Bachir; Michael F Walsh; Carolyn D Applegate; Reid Thompson; Marc K Halushka; Anne M Murphy; Meral Gunay-Aygun
Journal:  Am J Med Genet A       Date:  2012-05-14       Impact factor: 2.802

5.  SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations.

Authors:  Francesca Lepri; Alessandro De Luca; Lorenzo Stella; Cesare Rossi; Giuseppina Baldassarre; Francesca Pantaleoni; Viviana Cordeddu; Bradley J Williams; Maria L Dentici; Viviana Caputo; Serenella Venanzi; Michela Bonaguro; Ines Kavamura; Maria F Faienza; Alba Pilotta; Franco Stanzial; Francesca Faravelli; Orazio Gabrielli; Bruno Marino; Giovanni Neri; Margherita Cirillo Silengo; Giovanni B Ferrero; Isabella Torrrente; Angelo Selicorni; Laura Mazzanti; Maria C Digilio; Giuseppe Zampino; Bruno Dallapiccola; Bruce D Gelb; Marco Tartaglia
Journal:  Hum Mutat       Date:  2011-04-28       Impact factor: 4.878

6.  Analysis of Gene Expression Variance in Schizophrenia Using Structural Equation Modeling.

Authors:  Anna A Igolkina; Chris Armoskus; Jeremy R B Newman; Oleg V Evgrafov; Lauren M McIntyre; Sergey V Nuzhdin; Maria G Samsonova
Journal:  Front Mol Neurosci       Date:  2018-06-11       Impact factor: 5.639

7.  Alternative splicing of jnk1a in zebrafish determines first heart field ventricular cardiomyocyte numbers through modulation of hand2 expression.

Authors:  Adrian Santos-Ledo; Sam Washer; Tamil Dhanaseelan; Lorraine Eley; Ahlam Alqatani; Paul W Chrystal; Tania Papoutsi; Deborah J Henderson; Bill Chaudhry
Journal:  PLoS Genet       Date:  2020-05-18       Impact factor: 5.917

8.  In-Silico and In-Vitro Analysis of Human SOS1 Protein Causing Noonan Syndrome - A Novel Approach to Explore the Molecular Pathways.

Authors:  Vinoth Sigamani; Sheeja Rajasingh; Narasimman Gurusamy; Arunima Panda; Johnson Rajasingh
Journal:  Curr Genomics       Date:  2021-12-31       Impact factor: 2.689

9.  Digenic inheritance of subclinical variants in Noonan Syndrome patients: an alternative pathogenic model?

Authors:  Luca Ferrari; Eleonora Mangano; Maria Teresa Bonati; Ilaria Monterosso; Daniele Capitanio; Federica Chiappori; Ilaria Brambilla; Cecilia Gelfi; Cristina Battaglia; Roberta Bordoni; Paola Riva
Journal:  Eur J Hum Genet       Date:  2020-06-08       Impact factor: 4.246

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.